ADVERTISEMENT
News June 2023
Study: MolecuLight® Led to Wound Treatment Plan Changes in More Than Half of Patients
MolecuLight Inc. recently announced a study in the International Wound Journal—the largest wound imaging study of real-world evidence—found that following fluorescence imaging, clinicians used objective information on the wound’s bacterial status to adjust the initially outlined treatment plans in 53 percent of patients. The company says the study describes single-timepoint treatment decisions made on 1,000 chronic wounds at 211 wound-care facilities across 36 US states.
In the study, MolecuLight notes clinicians initially evaluated the wounds based on clinical signs and symptoms and documented a treatment path. The wounds were then imaged using MolecuLight i:X® or DX™ devices to identify the presence and location of harmful bacterial loads. The study revealed that fluorescence signals indicating elevated bacterial loads were observed in 70.8% of the wounds, whereas only 29.6% showed clinical signs and symptoms of infection. As a result, a significant percentage of wounds with harmful bacterial levels were asymptomatic and lacked clinical signs and symptoms that could have been missed by clinicians.
Click here for more info.
Omeza Holdings Appoints Cynthia Flowers as President and CEO
Omeza Holdings, Inc. recently announced the appointment of Cynthia L. Flowers as its new President and CEO, effective May 1, 2023. Ms. Flowers was previously Chief Executive Officer of Ipsen North America, and has also has served as President of Eisai Pharmaceuticals, where she oversaw commercial operations, medical affairs and services, manufacturing, alliance management and other functions.
Flowers will also join the Omeza Board of Directors, and succeeds company founder Thomas E. Gardner as CEO, according to Omeza. Gardner will continue as a senior advisor to the Board through the end of 2024. Separately, Ronald G. Gelbman has resigned from the Board, for personal reasons, with effect May 1, 2023.
Click here for more info.